STEVEN TREON

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
    Zachary R Hunter
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, LG102, 44 Binney Street, Boston, MA 02215, USA
    Clin Lymphoma 5:246-9. 2005
  2. ncbi request reprint Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
    Evdoxia Hatjiharissi
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 7:286-90. 2007
  3. ncbi request reprint Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice
    Daniel Ditzel Santos
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Exp Hematol 35:1366-75. 2007
  4. doi request reprint MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, M547, 450 Brookline Ave, Boston, MA 02115, USA
    N Engl J Med 367:826-33. 2012
  5. doi request reprint Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 13:241-3. 2013
  6. doi request reprint Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 12:433-7. 2012
  7. pmc Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, M547, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:3830-5. 2009
  8. ncbi request reprint CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Lymphoma 5:273-7. 2005
  9. pmc Thalidomide and rituximab in Waldenstrom macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 112:4452-7. 2008
  10. ncbi request reprint Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, LG102, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:474-81. 2005

Research Grants

Detail Information

Publications83

  1. ncbi request reprint CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia
    Zachary R Hunter
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, LG102, 44 Binney Street, Boston, MA 02215, USA
    Clin Lymphoma 5:246-9. 2005
    ..These studies demonstrate that CD5, CD10, and CD23 are commonly found in WM and that their expression should not exclude the diagnosis of WM. Moreover, expression of CD23 may define a clinically distinct subset of patients with WM...
  2. ncbi request reprint Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy
    Evdoxia Hatjiharissi
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 7:286-90. 2007
    ..One possibility for this discrepancy might involve linkage of polymorphisms between FcgammaRIIa and FcgammaRIIIa...
  3. ncbi request reprint Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice
    Daniel Ditzel Santos
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Exp Hematol 35:1366-75. 2007
    ....
  4. doi request reprint MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, M547, 450 Brookline Ave, Boston, MA 02115, USA
    N Engl J Med 367:826-33. 2012
    ..Waldenström's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). The underlying mutation in this disorder has not been delineated...
  5. doi request reprint Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 13:241-3. 2013
    ..Routine screening of iron saturation levels may therefore identify patients with WM and severe iron deficiency who may be candidates for parenteral iron therapy...
  6. doi request reprint Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 12:433-7. 2012
    ..those receiving non–bortezomib-containing regimens. Bortezomib-containing regimens may therefore represent a more optimal treatment approach for patients with familial WM...
  7. pmc Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, M547, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:3830-5. 2009
    ..We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM)...
  8. ncbi request reprint CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Lymphoma 5:273-7. 2005
    ..No significant change in CD3+, CD4+, CD8+, and CD16+/CD56+ effector cell levels occurred following CHOP-R as assessed by multicolor flow cytometry...
  9. pmc Thalidomide and rituximab in Waldenstrom macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 112:4452-7. 2008
    ..Lower doses of thalidomide (ie, <or= 200 mg/day) should be considered given the high frequency of treatment-related neuropathy in this patient population. This trial is registered at www.clinicaltrials.gov as #NCT00142116...
  10. ncbi request reprint Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, LG102, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:474-81. 2005
    ..Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-mediated cytotoxicity, and may therefore influence responses to rituximab...
  11. ncbi request reprint Clinical responses to sildenafil in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, nLG102, 44 Binney Street, Boston, MA 02115, USA
    Clin Lymphoma 5:205-7. 2004
    ..These studies suggest that sildenafil may be an active agent in the treatment of WM...
  12. ncbi request reprint Extended rituximab therapy in Waldenström's macroglobulinemia
    S P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Ann Oncol 16:132-8. 2005
    ..Major response rates of 30% have been reported in most studies with standard dose rituximab, i.e. 4 weekly infusions at 375 mg/m(2)/week...
  13. doi request reprint Lenalidomide and rituximab in Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:355-60. 2009
    ..We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinemia (WM) patients naive to either agent...
  14. doi request reprint How I treat Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 114:2375-85. 2009
    ..Newer agents, such as bendamustine and everolimus, can also be considered in the treatment of WM...
  15. ncbi request reprint Characterization of familial Waldenstrom's macroglobulinemia
    S P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 17:488-94. 2006
    ..Familial clustering of B-cell disorders among Waldenström's macroglobulinemia (WM) patients has been reported, though the frequency and any differences in disease manifestation for familial patients remain to be defined...
  16. doi request reprint Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen
    Steven P Treon
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 154:357-62. 2011
    ..Prospective studies aimed at clarifying the role of M-Rituximab therapy in WM patients are needed to confirm these findings...
  17. pmc Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab
    Steven P Treon
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 118:276-81. 2011
    ..Late AITP is a newly recognized complication of alemtuzumab in this patient population. This study is registered at www.clinicaltrials.gov as NCT00142181...
  18. doi request reprint Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinaemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 154:223-8. 2011
    ..The attainment of CR/VGPR was associated with significantly longer PFS in rituximab-naïve WM patients undergoing rituximab-based therapy, and was predicted by polymorphisms in FCGR3A...
  19. pmc Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 113:3673-8. 2009
    ..This study is registered at clinicaltrials.gov as NCT00020800...
  20. doi request reprint Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia
    Steven P Treon
    Dana Farber Cancer Institute, Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Boston, MA 02115, USA
    Clin Lymphoma Myeloma Leuk 11:133-5. 2011
    ..Bendamustine is active and produces durable responses in previously treated WM, both as monotherapy and with CD20-directed monoclonal antibodies...
  21. ncbi request reprint Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 13:3320-5. 2007
    ..Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such, novel therapeutic agents are needed for the treatment of WM...
  22. ncbi request reprint Novel agents in the treatment of Waldenström's macroglobulinemia
    Steven P Treon
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 7:S199-206. 2007
    ..This report provides an update on biologic studies and clinical efforts for the development of these novel agents in the treatment of Waldenström's macroglobulinemia...
  23. ncbi request reprint Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute LG102, 44 Binney Street, Boston, MA 02115, USA
    Blood 107:3442-6. 2006
    ....
  24. ncbi request reprint Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia
    S P Treon
    Waldenstrom s Macroglobulinemia Program, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02116, USA
    Ann Oncol 15:1481-3. 2004
    ..Paradoxically, we have observed that serum IgM levels can abruptly rise following rituximab therapy in patients with WM, and can often lead to morbidity on the basis of hyperviscosity...
  25. doi request reprint Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia
    Leukothea Ioakimidis
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 9:62-6. 2009
    ..The use of CP-R might provide analogous treatment responses to more intense cyclophosphamide-based regimens while minimizing treatment-related complications in patients with WM...
  26. pmc Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications
    Masood A Shammas
    Veterans Administration Boston Health Care System, and Dana Farber Cancer Institute Harvard Medical School, 44 Binney Street, D1B25, Boston, MA 02115, USA
    Blood 108:2804-10. 2006
    ..Expression of related genes at the protein level were also confirmed by Western blot analysis. These data demonstrate potent and specific antimyeloma activity of EGCG and provide the rationale for its clinical evaluation...
  27. ncbi request reprint Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:11712-20. 2005
    ....
  28. ncbi request reprint Novel biologically based therapies for Waldenstrom's macroglobulinemia
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:309-12. 2003
    ..These molecular studies provide a framework for rational design of the next generation of combination therapies for WM...
  29. pmc Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:1422-8. 2010
    ..This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory Waldenström macroglobulinemia (WM)...
  30. pmc Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  31. pmc Targeting NF-kappaB in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 111:5068-77. 2008
    ..Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-kappaB pathway...
  32. doi request reprint Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
    Aldo M Roccaro
    Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:1849-58. 2008
    ..Whether resveratrol could inhibit proliferation or induce cytotoxicity in Waldenström's macroglobulinemia (WM) was investigated...
  33. doi request reprint Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Am J Hematol 85:670-4. 2010
    ..No grade 3 or 4 neuropathy occurred. The combination of weekly bortezomib and rituximab exhibited significant activity and minimal neurological toxicity in patients with untreated WM...
  34. ncbi request reprint Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:6689-96. 2003
    ..It therefore provides a valuable in vivo system to elucidate the molecular mechanisms underlying the marked osteotropism of MM, particularly for the axial skeleton, and for assessment of in vivo activity of novel anti-MM therapeutics...
  35. pmc Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
    Irene M Ghobrial
    Dana Farber Cancer Center, Boston, MA, USA
    J Clin Oncol 28:1408-14. 2010
    ..CONCLUSION Everolimus has high single-agent activity with an overall response rate of 70% and manageable toxicity in patients with relapsed WM and offers a potential new therapeutic strategy for this patient group...
  36. pmc Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Blood 111:4752-63. 2008
    ..Theses studies enhance our understanding of the biologic role of the proteasome pathway in WM, and provide the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM...
  37. pmc The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 110:4417-26. 2007
    ..These results provide understanding of biological effects of Akt pathway in WM and provide the framework for clinical evaluation of perifosine in WM patients...
  38. pmc Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
    Evdoxia Hatjiharissi
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:2561-4. 2007
    ..These results suggest that individuals expressing at least one valine at FcgammaRIIIa-158 might, in part, have better clinical outcomes due to increased CD16 expression, rituximab binding, and rituximab-mediated ADCC...
  39. ncbi request reprint Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
    Toshiaki Hayashi
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 128:192-203. 2005
    ..These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM...
  40. doi request reprint Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 27:250-5. 2009
    ....
  41. doi request reprint Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:626-34. 2009
    ..Finally, we demonstrate that ER stress inducer synergizes with other agents used in the treatment of WM. These preclinical studies provide a framework for further evaluation of ER stress inducing agents as therapeutic agents in WM...
  42. ncbi request reprint Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations
    Steven P Treon
    Dana Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston 02115, USA
    Semin Oncol 30:248-52. 2003
    ..Combined mAb therapy might be a useful approach to cope with this variation, and could be tailored to target all members of the tumor clone for an individual patient...
  43. pmc A SCID-hu in vivo model of human Waldenström macroglobulinemia
    Pierfrancesco Tassone
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1341-5. 2005
    ..This model, therefore, recapitulates the in vivo biology of WM and allows the study of novel investigational drugs targeting WM cells in the huBM milieu...
  44. doi request reprint Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia
    Bryan T Ciccarelli
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Lymphoma Myeloma 9:56-8. 2009
    ..As such, we attempted to delineate its potential role in WM patients experiencing a rituximab-induced IgM flare and following plasmapheresis...
  45. doi request reprint Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia
    Marcel N Menke
    Schepens Retina Associates Foundation, Boston, Massachusetts 02215, USA
    Invest Ophthalmol Vis Sci 49:1157-60. 2008
    ..Plasmapheresis is known to reduce serum viscosity (SV) and IgM levels. The purpose of this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal hemodynamic parameters in patients with WM...
  46. doi request reprint Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia
    Marcel N Menke
    Schepens Retina Associates Foundation, Boston, MA, USA
    Clin Lymphoma Myeloma 9:100-3. 2009
    ..In addition, the effect of plasmapheresis on HVS-related retinopathy was tested...
  47. doi request reprint Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
    Clin Lymphoma Myeloma 9:71-3. 2009
    ....
  48. doi request reprint Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
    Xavier Leleu
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School Boston, MA 02115, USA
    Leuk Lymphoma 49:1104-7. 2008
    ..This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients...
  49. ncbi request reprint CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders
    Daniel Ditzel Santos
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute
    Clin Lymphoma Myeloma 6:478-83. 2006
    ..One potential target of alemtuzumab is bone marrow mast cells (BMMCs), which provide growth and survival signaling for WM lymphoplasmacytic cells...
  50. ncbi request reprint Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:156-60. 2003
    ..These proteomic studies pave the way for a more comprehensive insight into the molecular basis of WM versus other B-cell malignancies...
  51. ncbi request reprint Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia
    Marcel N Menke
    Schepens Retina Associates Foundation, Boston, MA 02215, USA
    Arch Ophthalmol 124:1601-6. 2006
    ..To determine the earliest retinal changes associated with Waldenström macroglobulinemia (WM) and to ascertain the serum IgM and serum viscosity (SV) levels at which these changes occur...
  52. ncbi request reprint CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications
    Steven P Treon
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Immunother 25:72-81. 2002
    ..Furthermore, IFN-gamma induces CD20 expression on MM BMPCs and B cells and facilitates rituximab binding to MM BMPCs, providing the rationale for clinical trials to examine its use with CD20-directed serotherapies in MM...
  53. pmc CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia
    Allen W Ho
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 112:4683-9. 2008
    ..The results of these studies demonstrate a functional role for sCD27 in WM pathogenesis, along with its utility as a surrogate marker of disease and a target in the treatment of WM...
  54. ncbi request reprint Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia
    Anne Sophie Moreau
    Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 109:4964-72. 2007
    ..028). Our studies therefore show that enzastaurin has significant antitumor activity in WM both in vitro and in vivo, providing the framework for clinical trials to improve patient outcome in WM...
  55. ncbi request reprint Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2846-52. 2004
    ..1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM...
  56. ncbi request reprint Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:7174-9. 2006
    ..The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed...
  57. ncbi request reprint Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Mayer Bldg, Boston, MA 02115, USA
    Blood 99:2162-71. 2002
    ..Our data set a framework for the clinical use of approaches that sensitize MM cells to TRAIL by agents that inhibit FLIP and cIAP-2 expression or augment caspase-8 activity...
  58. doi request reprint The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
    Anne Sophie Moreau
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 142:775-85. 2008
    ..Our studies therefore support our earlier observation of statin-mediated anti-WM activity and provide the framework for future clinical trials testing simvastatin in WM...
  59. ncbi request reprint Report of the Third International Workshop on Waldenstrom's macroglobulinemia
    Steven P Treon
    Bing Program for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA
    Clin Lymphoma 5:215-6. 2005
  60. ncbi request reprint Infectious complications associated with alemtuzumab use for lymphoproliferative disorders
    Stanley I Martin
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Infect Dis 43:16-24. 2006
    ..Alemtuzumab is an emerging therapy for refractory lymphoproliferative disorders. The associated long-term risks of infection remain poorly defined...
  61. ncbi request reprint Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4525-30. 2002
    ..These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM...
  62. ncbi request reprint Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells
    Toshiaki Hayashi
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 121:592-6. 2003
    ..This study, therefore, both demonstrates that rhuCD40 mAb triggers autologous ADCC against patient MM cells and provides the framework for the clinical evaluation of rhuCD40 mAb immunotherapy to improve patient outcome in MM...
  63. ncbi request reprint CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2762-9. 2003
    ....
  64. ncbi request reprint Proteomic analysis of waldenstrom macroglobulinemia
    Evdoxia Hatjiharissi
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 67:3777-84. 2007
    ..This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics...
  65. ncbi request reprint Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4079-86. 2002
    ..These studies provide the framework for targeting NF-kappaB activity in novel biologically based therapies for MM...
  66. ncbi request reprint Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Br J Haematol 125:343-52. 2004
    ..These studies therefore demonstrated that MM/DC FC can trigger an autologous immune response to MM cells and formed the framework for a clinical trial currently underway...
  67. doi request reprint Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia and Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 145:59-63. 2009
    ..These data depict for the first time a heterogeneous expression pattern of the genes involved in late differentiation process of plasma cells in patients with WM and propose a role of XBP1-ERN1alpha in WM pathogenesis...
  68. ncbi request reprint Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma
    Steven P Treon
    Dana Farber Cancer Institute, Boston, MA, USA
    Cancer Treat Res 142:211-42. 2008
  69. ncbi request reprint Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia
    Xavier Leleu
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Am J Hematol 82:83-4. 2007
    ..None of 100 randomly tested WM patients in this study tested positive for HCV by either analytical method. Our results therefore demonstrate a lack of association between HCV and WM...
  70. pmc IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia
    Zachary R Hunter
    Bing Center for Waldenstrom s Macroglobulinemia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Haematologica 95:470-5. 2010
    ..Hypogammaglobulinemia is common in Waldenström's macroglobulinemia. The etiology of this finding remains unclear, but it has been speculated to be based on tumor-induced suppression of the 'uninvolved' immunoglobulin production..
  71. ncbi request reprint The malignant clone in Waldenstrom's macroglobulinemia
    Jitra Kriangkum
    Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada
    Semin Oncol 30:132-5. 2003
    ..The lack of clonotypic transcripts suggests that the majority of these circulating B cells were polyclonal and were not part of the WM clone, indicating that monitoring of clonotypic IgM provides the most accurate identifier of WM cells...
  72. ncbi request reprint Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences
    Jitra Kriangkum
    Departments of Oncology, Cross Cancer Institute and Medicine, University of Alberta, Edmonton, Canada
    Clin Cancer Res 13:2005-13. 2007
    ..Malignant B lineage cells in Waldenstrom's macroglobulinemia (WM) express a unique clonotypic IgM VDJ. The occurrence of biclonal B cells and their clonal relationships were characterized...
  73. ncbi request reprint Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood
    Jitra Kriangkum
    Department of Medicine, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
    Blood 104:2134-42. 2004
    ....
  74. ncbi request reprint Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Morie A Gertz
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:121-6. 2003
    ..11) Corticosteroids may be useful in the treatment of symptomatic mixed cryoglobulinemia. (12) Splenectomy is rarely indicated but has been used to manage painful splenomegaly and hypersplenism...
  75. ncbi request reprint Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
    Eva Kimby
    Karolinska University Hospital, Stockholm, Sweden
    Clin Lymphoma Myeloma 6:380-3. 2006
    ..The new criteria should therefore help in better delineating responses to therapy in patients with WM, particularly with the wide use of nucleoside analogues and biologically based agents for this disease...
  76. ncbi request reprint Diagnosis and management of Waldenstrom's macroglobulinemia
    Meletios A Dimopoulos
    Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, 14561, Greece
    J Clin Oncol 23:1564-77. 2005
    ..To review the diagnostic criteria, prognostic factors, response criteria, and treatment options of patients with Waldenstrom's macroglobulinemia (WM)...
  77. ncbi request reprint Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Donna Weber
    University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Semin Oncol 30:127-31. 2003
    ....
  78. ncbi request reprint Defining Waldenstrom's macroglobulinemia
    Steven P Treon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 30:107-9. 2003
  79. ncbi request reprint Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:5673-83. 2002
    ..Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1...
  80. doi request reprint Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia
    Anne Sophie Moreau
    Service des Maladies du Sang, CHRU, Lille, France
    Eur J Haematol 80:503-9. 2008
    ..Beta-2 microglobulin (b2m) is a major prognostic factor in WM and the heavy chain of HLA class I molecules, which are known to have immunosuppressive properties and have been implicated in the pathogeny of several malignancies...
  81. ncbi request reprint Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Robert A Kyle
    Mayo Clinic, Rochester, MN, USA
    Semin Oncol 30:116-20. 2003
    ..However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM...
  82. ncbi request reprint Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia
    Sophia Adamia
    Departments of Oncology and Medicine, University of Alberta and Cross Cancer Institute, Edmonton, Alberta T6G 1Z2, Canada
    Clin Lymphoma 5:253-6. 2005
    ..Study of a larger group of patients and healthy donors is needed to confirm these speculations and to evaluate the prognostic significance of these findings...
  83. ncbi request reprint Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
    Roger G Owen
    Leeds General Infirmary, Leeds, UK
    Semin Oncol 30:110-5. 2003
    ..Patients with clinical features attributable to IgM monoclonal gammopathy but no overt evidence of lymphoma are considered to constitute a distinct clinical group and the term "IgM-related disorders" is proposed...

Research Grants1

  1. NOVEL SEROTHERAPY STRATEGIES--PLASMA CELL MALIGNANCIES
    STEVEN TREON; Fiscal Year: 2004
    ..Analogous to our work with Muc-1, we will also attempt to identify other PCD selective targets by generating and examining mAbs specific to the plasma cell glycoform of CD138. ..